Prostate Cancer Molecular Subtypes: ERG, SPOP, and Beyond
- Why are molecular subtypes important?
- ERG fusion (TMPRSS2-ERG) – most common alteration
- SPOP mutations – 10-15%, distinct clinical features
- CHD1 loss – 5-10%, SPOP-like phenotype
- Other subtypes – FOXA1, IDH1, TP53, PTEN loss
- Molecular classification systems – PAM50, Decipher, Prolaris
- Clinical implications – prognosis, targeted therapies
- Future directions – precision medicine
- Interactive FAQ – 9 questions about prostate cancer molecular subtypes
Why are molecular subtypes important?
Prostate cancer is a heterogeneous disease with variable clinical outcomes. Traditional risk stratification (PSA, Gleason score, stage) does not fully capture this heterogeneity. Molecular subtyping identifies distinct biological classes with different:
- Prognosis (risk of progression, metastasis, death)
- Response to therapy (hormone therapy, chemotherapy, PARP inhibitors)
- Potential for targeted therapies
ERG fusion (TMPRSS2-ERG) – most common alteration
The TMPRSS2-ERG gene fusion is the most common molecular alteration in prostate cancer, occurring in approximately 50% of cases.
Mechanism:
- Androgen-responsive promoter of TMPRSS2 fuses with the ERG oncogene
- Results in androgen-driven overexpression of ERG (an ETS transcription factor)
- Drives cellular proliferation and invasion
Clinical features:
- Associated with younger age at diagnosis
- More common in white men (vs. African descent)
- Correlates with higher Gleason score and stage
- Prognosis: Mixed evidence – some studies show worse outcomes, others no difference
Clinical utility:
- ERG expression by IHC can be used as a diagnostic marker (highly specific for cancer)
- Potential therapeutic target (ERG inhibitors in development)
SPOP mutations – 10-15%, distinct clinical features
SPOP (Speckle-type POZ protein) mutations are the most common point mutations in primary prostate cancer (10-15% of cases).
Mechanism:
- SPOP is an E3 ubiquitin ligase adaptor
- Mutations occur in the substrate-binding domain (hotspot mutations)
- Result in altered protein degradation and activation of PI3K/mTOR and AR signaling
Clinical features:
- Mutually exclusive with ERG fusions (SPOP-mutant cancers are ERG-negative)
- Associated with younger age, higher Gleason score
- Better prognosis than ERG-positive cancers (lower risk of metastasis)
- More common in men of European descent
Clinical utility:
- SPOP-mutant cancers may be more sensitive to PARP inhibitors (preclinical data)
- Potential for targeted therapy (SPOP inhibitors in development)
CHD1 loss – 5-10%, SPOP-like phenotype
CHD1 (Chromodomain Helicase DNA-binding protein 1) loss occurs in 5-10% of prostate cancers, often overlapping with SPOP mutations.
Mechanism:
- CHD1 is a chromatin remodeler involved in DNA repair and transcription
- Loss occurs via deletion or mutation
- Leads to genomic instability and altered androgen receptor signaling
Clinical features:
- Strongly associated with SPOP mutations (co-occurring)
- ERG-negative, ETS-negative subtype
- Associated with higher Gleason score
- Prognosis: Intermediate (between ERG and SPOP)
Other subtypes – FOXA1, IDH1, TP53, PTEN loss
FOXA1 mutations:
- Occur in 5-10% of prostate cancers
- FOXA1 is a pioneer factor for androgen receptor
- Associated with aggressive disease and poor prognosis
IDH1 mutations:
- Rare (<1%) in prostate cancer
- More common in other cancers (gliomas, AML)
- May be targetable with IDH inhibitors (ivosidenib, enasidenib)
TP53 mutations:
- Occur in 10-20% of localized prostate cancer; up to 50% in metastatic disease
- Associated with aggressive disease, poor prognosis, and castration resistance
PTEN loss:
- Occurs in 20-30% of localized prostate cancer; up to 50% in metastatic disease
- Loss via deletion or mutation
- Activates PI3K/AKT/mTOR pathway
- Associated with worse prognosis and resistance to hormone therapy
- Potential target for AKT inhibitors (ipatasertib, capivasertib)
Molecular classification systems – PAM50, Decipher, Prolaris
PAM50 (Prostate Cancer Molecular Subtyping):
- Based on gene expression profiling
- Identifies subtypes: luminal A, luminal B, basal, and others
- Luminal B subtype has worse prognosis than luminal A
Decipher (Genomic Classifier):
- 22-gene expression panel
- Predicts risk of metastasis after surgery
- Clinically validated; guides adjuvant therapy decisions
Prolaris (Cell Cycle Progression Score):
- 31-gene expression panel (cell cycle genes)
- Predicts prostate cancer-specific mortality
- Used for risk stratification in localized prostate cancer
Clinical implications – prognosis, targeted therapies
Prognostic implications:
- SPOP mutations: Better prognosis (lower risk of metastasis)
- PTEN loss, TP53 mutations: Worse prognosis, higher risk of progression
- ERG fusions: Prognostic value unclear (likely neutral)
Therapeutic implications:
- PARP inhibitors (olaparib, rucaparib): Effective in HRR-mutated cancers (BRCA2, ATM, PALB2). SPOP-mutant cancers may also be sensitive.
- AKT inhibitors: For PTEN-loss cancers (ipatasertib, capivasertib)
- ERG inhibitors: In development (clinical trials)
- IDH inhibitors: For rare IDH1-mutant cancers
Future directions – precision medicine
The future of prostate cancer management lies in precision medicine:
- Integration of molecular subtyping into routine clinical practice
- Development of targeted therapies for specific subtypes (ERG, SPOP, PTEN)
- Liquid biopsies (circulating tumor DNA) for real-time monitoring of molecular evolution
- Combination therapies targeting multiple pathways
- Artificial intelligence to integrate genomic, pathologic, and clinical data
Interactive FAQ – Prostate cancer molecular subtypes
ERG fusion (TMPRSS2-ERG) – occurs in approximately 50% of prostate cancers.
SPOP mutations define a distinct subtype (10-15%) with better prognosis and potential sensitivity to PARP inhibitors.
Prognostic value is unclear – some studies show worse outcomes, others no difference. ERG is mainly a diagnostic marker.
A 22-gene expression panel that predicts risk of metastasis after radical prostatectomy. Guides adjuvant therapy decisions.
HRR mutations – BRCA1/2, ATM, PALB2, and possibly SPOP mutations.
Loss of the PTEN tumour suppressor gene (20-50% of cancers). Associated with aggressive disease and resistance to hormone therapy.
Yes – ERG fusions are more common in white men; SPOP mutations are also more common in white men. African-descent men have different molecular profiles.
A gene expression-based classification system that identifies luminal A, luminal B, and basal subtypes of prostate cancer.
Not all – but recommended for men with metastatic disease (to guide PARP inhibitor therapy) and select high-risk localized cancers.
Disclaimer: This information is for educational purposes and intended for clinicians and researchers. Molecular subtyping is an evolving field. Consult primary literature for up-to-date recommendations.